DC-CIK (WT1)

**DC-CIK (WT1)** is a patient-specific cellular immunotherapy developed by Ever Supreme Bio Technology. The product consists of autologous dendritic cells and cytokine-induced killer cells co-cultured ex vivo, with dendritic cells loaded with Wilms tumor 1 peptide antigen. The antigen-loaded dendritic cells present WT1-associated tumor antigen and activate CIK cells, combining WT1-directed immune recognition with the broad cytotoxic activity of CIK cells. Ever Supreme identifies the product as a distinct immune-cell-platform product, with an optimized approximately two-week DC/CIK co-culture process and use in patients for whom autologous tumor tissue is unavailable. ([en.ever-supreme.com.tw](https://en.ever-supreme.com.tw/products_detail/2/1)) In Taiwan, hospital materials identify it as a Ministry of Health and Welfare-approved specific medical technology for stage IV breast cancer and colorectal cancer; this is not equivalent to a conventional marketing authorization for a standardized pharmaceutical product. ([sub.chimei.org.tw](https://sub.chimei.org.tw/57040/index.php/news/33-%E6%9C%AC%E9%99%A2%E7%B4%B0%E8%83%9E%E6%B2%BB%E7%99%82%E6%8A%80%E8%A1%93%E6%96%B0%E5%A2%9Edc-cik-wt1))

Other names

DC-CIK WT1Dendritic Cell-Cytokine Induced Killer Cell (WT1)